Expert Series｜ADCs-Magic Bullets Becomes Reality

Home / Resources / Expert Series｜ADCs-Magic Bullets Becomes Reality

Cancer is one of the leading causes of death globally, and antibody-drug conjugates (ADCs) have moved from theory to reality, facilitating in the application of a biological “magic bullet” for treatment. Although ADCs present a superior alternative to traditional therapies, by combining targeted drug delivery and cytotoxicity into a single agent, the promising characteristics of these drugs are not without their own challenges and limitations.

The current ADC landscape features 654 drugs, with only 13 ADCs approved to date, of which successes have been observed with hurdles where initial approvals did not signify the end of their development journey. With well over half of the ADC landscape in preclinical development, there is growing interest for the next upcoming candidate, though it remains to be seen, as relatively few candidates reach pivotal trials.

Watch on demand webinar with Heidi Chen for a brief dive into antibody drug conjugates in cancer treatment.

First Name *

Last Name *

Company *

Job Title *

Business Email Address *

Business Phone *

Country *

Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you.

Your download should open in a new window. You can also manually download by clicking the button below.

特別講演者

Heidi Chen

Associate Director, Research & Commercial Services, Citeline

Heidi Chen supports client engagement with Citeline content through a deep understanding of customer business needs, seasoned expertise in proprietary platforms, market analysis, and commercial activities. She oversees Citeline's production of customized Platinum Datapacks across hot topic facing industry today.

Heidi draws from her pharmaceutical industry experience as a drug discover scientist and over two decades of therapy-area expertise in CNS, immunology, and ophthalmology. Within this remit, she collaborates across various functional groups within Citeline, and contributes towards projects such as consulting engagements, webinars, and thought leadership white papers.